FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不 ...

Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, intending to repurchase 164,700 A-shares at a total cost of 5.9998 million yuan [1] Group 1 - The company plans to execute the buyback on November 4, 2025 [1] - The total expenditure for the buyback is approximately 5.9998 million yuan [1] - The number of shares to be repurchased is 164,700 [1]

Core Viewpoint - Lijun Pharmaceutical (01513.HK) announced a share buyback plan, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Buyback Details - The company plans to repurchase 164,700 A shares at a total cost of RMB 6 million [1] - The buyback price per share is set between RMB 36.16 and RMB 36.71 [1]

Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, intending to repurchase 164,700 A-shares at a cost of 5.9998 million yuan, scheduled for November 4, 2025 [1] Summary by Category - **Company Actions** - The company plans to spend 5.9998 million yuan to buy back 164,700 A-shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已 ...

Group 1 - The announcement pertains to the compliance inspection results of Lijun Group Fuzhou Fuxing Pharmaceutical Co., Ltd. regarding Good Manufacturing Practice (GMP) [3] - The inspection was conducted based on the Drug Administration Law and relevant regulations, with a focus on the production quality management standards [3] - The inspection covered the production lines for the raw material Vancomycin Hydrochloride, specifically the second and fourth production lines [4] Group 2 - The inspection took place from September 25 to September 27, 2025 [4] - The results indicate that the company’s production practices are compliant with the GMP standards [4] - The inspection was conducted at the company's facility located in Fuzhou, Fujian Province [4]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Group 1: Company Insights - Yaxing Integrated (603929.SH) reported a record high quarterly profit with a significant increase in gross margin, achieving a revenue of 1.425 billion yuan in Q3 2025, down 9% year-on-year but up 68% quarter-on-quarter, and a net profit of 282 million yuan, up 40% year-on-year and 257% quarter-on-quarter [10][12] - The company’s gross margin reached 27.5% in Q3 2025, a substantial increase of 7.1 percentage points from the previous quarter and 11.0 percentage points from the same period last year, indicating improved cost control in the Singapore market [10][12] - The company is expected to continue benefiting from significant orders in the semiconductor cleanroom engineering sector, with profit forecasts for 2025-2027 adjusted to 679 million, 1.007 billion, and 1.237 billion yuan respectively, reflecting a strong growth outlook [12] Group 2: Industry Trends - The automotive industry is experiencing a surge in intelligent technology, with companies like Xiaoma Zhixing and Wenyuan Zhixing preparing for IPOs in Hong Kong, and Junsheng Electronics securing a global order worth 5 billion yuan in automotive intelligence [16][19] - The pharmaceutical sector is focusing on cardiovascular diseases, with multinational pharmaceutical companies intensifying their efforts on PCSK9 and Lp(a) targets, projecting a global market size for PCSK9 inhibitors to reach 11-19 billion USD and Lp(a) inhibitors to reach 3-7 billion USD [20][21] - The electronic gas market is expanding, driven by the demand for semiconductor manufacturing, with companies like Guanggang Gas (688548.SH) reporting a 14.85% increase in revenue year-to-date, indicating a robust growth trajectory in the electronic gas sector [24][25]

证券日报网讯11月3日晚间，丽珠集团（000513）发布公告称，截至2025年10月31日，公司通过集中竞 价交易方式回购了公司A股股份共计15，376，845股，占公司总股本的比例为1.70%。 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6][20]. Core Insights - The company has shown steady growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 9.116 billion yuan (+0.4%) and net profit at 1.754 billion yuan (+4.9%) [1][7]. - Core product sales are stable, and innovative products are progressing towards commercialization, with significant developments in various therapeutic areas [2][18]. - The company is expected to maintain its previous profit forecasts, with projected revenues of 12.337 billion yuan, 13.052 billion yuan, and 13.938 billion yuan for 2025, 2026, and 2027 respectively, reflecting growth rates of 4.4%, 5.8%, and 6.8% [4][20]. Financial Performance Summary - For the first three quarters of 2025, the company achieved a gross margin of 66.4% (+0.6 percentage points) and a net profit margin of 23.4% (+1.9 percentage points) [15]. - The company’s earnings per share (EPS) for 2025 is projected to be 2.41 yuan, with a corresponding price-to-earnings (PE) ratio of 16.1 [5][20]. - The return on equity (ROE) is expected to increase from 13.9% in 2023 to 19.3% by 2027 [5][22]. Product Development and Pipeline - The company’s innovative product LZM012, an IL-17A/F monoclonal antibody, has met its primary clinical endpoint and is expected to submit a New Drug Application (NDA) in Q4 2025 [3][19]. - The company’s core products in the formulation segment, including those in digestive, psychiatric, and traditional Chinese medicine fields, have all seen year-on-year sales growth [2][18].